GB0425972D0 - Biological products - Google Patents

Biological products

Info

Publication number
GB0425972D0
GB0425972D0 GBGB0425972.7A GB0425972A GB0425972D0 GB 0425972 D0 GB0425972 D0 GB 0425972D0 GB 0425972 A GB0425972 A GB 0425972A GB 0425972 D0 GB0425972 D0 GB 0425972D0
Authority
GB
United Kingdom
Prior art keywords
biological products
tnfalpha
signalling
present
selectively inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0425972.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Priority to GBGB0425972.7A priority Critical patent/GB0425972D0/en
Publication of GB0425972D0 publication Critical patent/GB0425972D0/en
Priority to JP2007542113A priority patent/JP2008521783A/ja
Priority to EP05807990.6A priority patent/EP1817344B9/en
Priority to PCT/GB2005/004511 priority patent/WO2006056779A2/en
Priority to ES05807990.6T priority patent/ES2553129T3/es
Priority to US11/791,498 priority patent/US9840556B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0425972.7A 2004-11-25 2004-11-25 Biological products Ceased GB0425972D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0425972.7A GB0425972D0 (en) 2004-11-25 2004-11-25 Biological products
JP2007542113A JP2008521783A (ja) 2004-11-25 2005-11-24 ｐ５５Ｒを介するＴＮＦαシグナル伝達を選択的に抑制する抗ＴＮＦα抗体
EP05807990.6A EP1817344B9 (en) 2004-11-25 2005-11-24 ANTI-TNF ALPHA ANTIBODIES WHICH SELECTIVELY INHIBIT TNF ALPHA SIGNALLING THROUGH THE p55R
PCT/GB2005/004511 WO2006056779A2 (en) 2004-11-25 2005-11-24 ANTI-TNF ALPHA ANTIBODIES WHICH SELECTIVELY INHIBIT TNF ALPHA SIGNALLING THROUGH THE p55R
ES05807990.6T ES2553129T3 (es) 2004-11-25 2005-11-24 Anticuerpos anti-TNF alfa que inhiben de manera selectiva la señalización de TNF alfa por medio del p55R
US11/791,498 US9840556B2 (en) 2004-11-25 2005-11-24 Anti-TNF alpha antibodies which selectively inhibit TNF alpha signalling through the p55R

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0425972.7A GB0425972D0 (en) 2004-11-25 2004-11-25 Biological products

Publications (1)

Publication Number Publication Date
GB0425972D0 true GB0425972D0 (en) 2004-12-29

Family

ID=33561379

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0425972.7A Ceased GB0425972D0 (en) 2004-11-25 2004-11-25 Biological products

Country Status (6)

Country Link
US (1) US9840556B2 (enExample)
EP (1) EP1817344B9 (enExample)
JP (1) JP2008521783A (enExample)
ES (1) ES2553129T3 (enExample)
GB (1) GB0425972D0 (enExample)
WO (1) WO2006056779A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523954D0 (en) * 2005-11-24 2006-01-04 Ucb Celltech Bioassays
WO2007060411A1 (en) * 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
WO2011026102A1 (en) * 2009-08-31 2011-03-03 Life Technologies Corporation Methods of bead manipulation and forming bead arrays
WO2011095174A1 (en) 2010-02-08 2011-08-11 Aarhus Universitet Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
SK376492A3 (en) 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
EP1077723A1 (en) 1998-05-18 2001-02-28 Applied Research Systems ARS Holding N.V. Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
DE19957065B4 (de) * 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE524196T1 (de) * 2001-10-16 2011-09-15 Macrogenics West Inc An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
AU2003225976A1 (en) 2002-03-26 2003-10-13 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用

Also Published As

Publication number Publication date
EP1817344B1 (en) 2015-08-26
US9840556B2 (en) 2017-12-12
US20080124342A1 (en) 2008-05-29
JP2008521783A (ja) 2008-06-26
ES2553129T3 (es) 2015-12-04
ES2553129T9 (es) 2016-02-22
EP1817344A2 (en) 2007-08-15
EP1817344B9 (en) 2016-02-10
WO2006056779A2 (en) 2006-06-01
WO2006056779A3 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
HUS1600037I1 (hu) Anti-IL-17 ellenanyagok
EP1648512A4 (en) ANTI-CD19 ANTIBODIES
MX339015B (es) Anticuerpos que se fijan a tweak.
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
GB2437009A (en) Ranking system
IL187316A0 (en) Anti-interleukin 2 antibodies
ITTO20040849A1 (it) Tubazione per carburante.
GB0517487D0 (en) Antibodies
WO2007001962A3 (en) Systems and methods for generating biological material
GB0425972D0 (en) Biological products
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
ITMI20031373A1 (it) Cassetti per detergenti con valvola distributrice incorporata.
ITPR20030089A1 (it) Valvola di omogeneizzazione.
MX2008001269A (es) Sistema de higiene.
FR2888843B1 (fr) Procede de preparation d'un diarylanthracene.
ITRM20040127A1 (it) Contenitore di sicurezza per campioni biologici.
ITFI20020191A1 (it) Contenitore per analisi batteriologiche.
ITRM20050364A1 (it) Genetic intelligent adaptive analysis "giada".
GB0505054D0 (en) Antibodies
GB0512278D0 (en) Antibodies
AU306687S (en) Bottle stopper
ITTV20030101A1 (it) Piatto con portabicchiere.
ITMI20030071A1 (it) Piatto in particolare per alimenti.
AU2961P (en) Kalka Triticum turgidum ssp. turgidum
AP2006003532A0 (en) Anti-VEGF antibodies.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)